clinical trial · NCT04766086
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
Pfizer·phase2·completed·n = 306
Group B Streptococcus InfectionsMultivalent Group B streptococcus vaccineTetanus, diphtheria, and acellular pertussis vaccinePlacebo
brief summary
This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.
started
Aug 12, 2022
primary completion
Apr 27, 2023
completion
Apr 27, 2023
last updated
May 24, 2024
official title
A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol